Back

Pharmacodynamic and pharmacokinetic profiles associated with switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the SWAP-6 study

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Antithrombotic therapy in acute coronary syndromes and PCI Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

6 More presentations in this session

Presentation thumbnail
Pattern of dual antiplatelet use and 12-month outcomes stratified by bleeding and ischemic risk in acute coronary syndrome patients undergoing percutaneous coronary intervention
Doctor A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Repeat coronary revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: Insights from the randomized TWILIGHT trial
Professor R. Mehran (New York City, US)
Abstract Slides Video
Presentation thumbnail
Mortality with bivalirudin plus a high-dose infusion versus heparin in patients with acute coronary syndrome
Doctor M. Galli (Rome, IT)
Abstract Slides Video
Presentation thumbnail
In vitro comparison of platelet aggregation between zalunfiban and selatogrel in healthy donors
Mr S. Rikken (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction
Doctor S. Godtfredsen (Aalborg, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy in acute coronary syndromes and PCI

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Session
Antiplatelet therapy: novel approaches for acute coronary syndrome and percutaneous coronary intervention
thumbnail
Congress Presentation
Cangrelor use in ticagrelor-loaded ST-elevation myocardial infarction patients with high residual platelet reactivity: a randomized controlled trial.
thumbnail
Congress Session
Late-breaking science on acute coronary syndromes

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources